13337-69-4

Basic information

• Product Name: Tetrahydroquinolinecarboxylicacid
• Synonyms: Tetrahydroquinolinecarboxylicacid;1,2,3,4-TETRAHYDROQUINOLINE-4-CARBOXYLIC ACID
• CAS NO: 13337-69-4
• Molecular Formula: C₁₀H₁₁NO₂
• Molecular Weight: 177.19984
• Mol File: 13337-69-4.mol
• Article Data: 5

Chemical Properties

• Melting Point: 217-218 °C
• Boiling Point: 362.536 °C at 760 mmHg
• Flash Point: 173.056 °C
• Appearance: /
• Density: 1.226 g/cm³
• Storage Temp.: 2-8°C(protect from light)
• PKA: 3.61±0.20(Predicted)
• CAS DataBase Reference: Tetrahydroquinolinecarboxylicacid(CAS DataBase Reference)
• NIST Chemistry Reference: Tetrahydroquinolinecarboxylicacid(13337-69-4)
• EPA Substance Registry System: Tetrahydroquinolinecarboxylicacid(13337-69-4)

Safety Data

• Hazard Codes: T
• Statements: 25-52
• Safety Statements: 45
• Hazardous Substances Data: 13337-69-4(Hazardous Substances Data)

Usage

General Description

Tetrahydroquinolinecarboxylic acid (THQ) is a chemical compound that belongs to a group of organic compounds known as quinolines and isoquinolines. It is typically used in the field of pharmaceuticals and serves as a valuable building block in medicinal chemistry, due to its potential applications in the development of therapeutic agents. THQ's core structure is comprised of a combination of benzene and pyridine which makes it also a crucial element in many biologically active compounds, leading to usages in the fields of biological and infection research. However, specific information on its toxicity, safety, and environmental effects is not widely available and more research is needed to ascertain these factors.

Upstream product

• 486-74-8 4-quinolinic acid 

Downstream Products

• 908264-29-9 (+/-)-1-(4-methoxy-benzoyl)-1,2,3,4-tetrahydro-quinoline-4-carboxylic acid 
• 24562-76-3 Ethyl 1,2,3,4-tetrahydroquinoline-4-carboxylate 
• 890839-41-5 C₁₇H₁₇NO₂ 

Relevant articles and documents

-

-

USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS

The present invention relates to the use of compounds of formula (I) R1 is hydrogen, tritium, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, amino or lower alkyl substituted by halogen; R2 is hydrogen, hydroxy or lower alkyl; X is N and Y is CH or CH2 or CH-lower alkyl or X is CH and Y is N; Q is CH2, O, NH, N-alkyl or N-SO2-alkyl or N-SO2-toluen-4-yl; W is CH2 or a bond are independently from one another 1, 2 or 3; when m is 2 or 3, R2 may m, n be the same or not; when n is 2 or 3, R1 may be the same or not; the dotted lines may each be independently from one another a bond or not; and to their pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers and tautomeric forms of compounds of formula (I) for the preparation of medicaments for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof

Compounds that are antagonists of the VR1 receptor, having formula (I) [image] or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A1, A2, A3, A4, R7, R8, R9, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.